What Right to Try Act means for pharmaceutical and biotech companies

US President Donald Trump speaks before signing the 'Right To Try Act'. Image credit: Nicholas Kamm

Pharmaceutical and biotechnology companies need to start preparing for the compliance and reporting requirements of a controversial new law.

US President Donald Trump on May 30 signed into law the Right to Try Act (H.R.5247), which will allow eligible patients, through drug manufacturers, to seek access to drugs that have not yet been approved by the Food and Drug Administration (FDA). In order to be eligible, a patient must be diagnosed with a disease or condition that they are likely to die from within a matter of months, or that causes significant irreversible morbidity likely to lead to a severely premature death.

The Right to Try Act was not met with unanimous approval. Prior to its passing, the bill was stalled in the House due to concerns for patient safety. Shortly after the Right to Try Act was signed, an updated version was introduced that added additional patient protections.

Related article:  Muscular dystrophy targeted with promising gene therapy

[T]he National Organization for Rare Disorders, an organization supporting more than 30 million patients with rare diseases, issued a statement to the House stating, “we have strongly opposed all Right to Try legislation, as we do not believe that it will safely and genuinely increase access to investigational therapies outside of clinical trials.”

Regardless of any lingering controversy, pharmaceutical and biotechnology companies will need to start preparing for the compliance requirements that this legislation brings.

Read full, original post: The ‘Right To Try Act’: Another Compliance Requirement For Pharma And Biotech Companies

Outbreak Daily Digest
Biotech Facts & Fallacies
Talking Biotech
Genetics Unzipped
ft covidresponseus feature

Video: Viewpoint: The US wrote the global playbook on the coronavirus and then ignored it

A year ago, the United States was regarded as the country best prepared for a pandemic. Our government had spent ...
mag insects image superjumbo v

Disaster interrupted: Which farming system better preserves insect populations: Organic or conventional?

A three-year run of fragmentary Armageddon-like studies had primed the journalism pumps and settled the media framing about the future ...
dead bee desolate city

Are we facing an ‘Insect Apocalypse’ caused by ‘intensive, industrial’ farming and agricultural chemicals? The media say yes; Science says ‘no’

The media call it the “Insect Apocalypse”. In the past three years, the phrase has become an accepted truth of ...
globalmethanebudget globalcarbonproject cropped x

Infographic: Cows cause climate change? Agriculture scientist says ‘belching bovines’ get too much blame

A recent interview by Caroline Stocks, a UK journalist who writes about food, agriculture and the environment, of air quality ...
organic hillside sweet corn x

Organic v conventional using GMOs: Which is the more sustainable farming?

Many consumers spend more for organic food to avoid genetically modified products in part because they believe that “industrial agriculture” ...
benjamin franklin x

Are most GMO safety studies funded by industry?

The assertion that biotech companies do the research and the government just signs off on it is false ...
gmo corn field x

Do GMO Bt (insect-resistant) crops pose a threat to human health or the environment?

Bt is a bacterium found organically in the soil. It is extremely effective in repelling or killing target insects but ...

Environmental Working Group: EWG challenges safety of GMOs, food pesticide residues

Known by some as the "Environmental Worrying Group," EWG lobbies for tighter GMO legislation and famously puts out annual "dirty dozen" list of fruits and ...
m hansen

Michael Hansen: Architect of Consumers Union ongoing anti-GMO campaign

Michael K. Hansen (born 1956) is thought by critics to be the prime mover behind the ongoing campaign against agricultural biotechnology at Consumer Reports. He is an ...
News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.
Send this to a friend